Sera Prognostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 04:11 pm EST
Share
Sera Prognostics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.042 million compared to USD 0.087 million a year ago. Net loss was USD 7.21 million compared to USD 10.71 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.35 a year ago.
For the nine months, sales was USD 0.265 million compared to USD 0.203 million a year ago. Net loss was USD 28.32 million compared to USD 34.44 million a year ago. Basic loss per share from continuing operations was USD 0.91 compared to USD 1.11 a year ago.
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant motherâs risk of delivering spontaneously before 37 weeksâ gestation.
SERA PROGNOSTICS, INC. 
